New insights into orthostatic hypotension in multiple system atrophy: a European multicentre cohort study

Objectives Orthostatic hypotension (OH) is a key feature of multiple system atrophy (MSA), a fatal progressive neurodegenerative disorder associated with autonomic failure, parkinsonism and ataxia. This study aims (1) to determine the clinical spectrum of OH in a large European cohort of patients with MSA and (2) to investigate whether a prolonged postural challenge increases the sensitivity to detect OH in MSA. Methods Assessment of OH during a 10 min orthostatic test in 349 patients with MSA from seven centres of the European MSA-Study Group (age: 63.6±8.8 years; disease duration: 4.2±2.6 years). Assessment of a possible relationship between OH and MSA subtype (P with predominant parkinsonism or C with predominant cerebellar ataxia), Unified MSA Rating Scale (UMSARS) scores and drug intake. Results 187 patients (54%) had moderate (>20 mm Hg (systolic blood pressure (SBP)) and/or >10 mm Hg (diastolic blood pressure (DBP)) or severe OH (>30 mm Hg (SBP) and/or >15 mm Hg (DBP)) within 3 min and 250 patients (72%) within 10 min. OH magnitude was significantly associated with disease severity (UMSARS I, II and IV), orthostatic symptoms (UMSARS I) and supine hypertension. OH severity was not associated with MSA subtype. Drug intake did not differ according to OH magnitude except for antihypertensive drugs being less frequently, and antihypotensive drugs more frequently, prescribed in severe OH. Conclusions This is the largest study of OH in patients with MSA. Our data suggest that the sensitivity to pick up OH increases substantially by a prolonged 10 min orthostatic challenge. These results will help to improve OH management and the design of future clinical trials.

[1]  R. Freeman,et al.  Droxidopa for neurogenic orthostatic hypotension randomized, placebo-controlled, phase 3 trial , 2014 .

[2]  Amy C. Arnold,et al.  Current Concepts in Orthostatic Hypotension Management , 2013, Current Hypertension Reports.

[3]  G. Lopane,et al.  Multiple system atrophy with prolonged survival: is late onset of dysautonomia the clue? , 2013, Neurological Sciences.

[4]  A. Gamboa,et al.  Angiotensin II, Independent of Plasma Renin Activity, Contributes to the Hypertension of Autonomic Failure , 2013, Hypertension.

[5]  Günther Deuschl,et al.  The natural history of multiple system atrophy: a prospective European cohort study , 2013, The Lancet Neurology.

[6]  Valeria Iodice,et al.  Autonomic dysfunction in parkinsonian disorders: assessment and pathophysiology , 2012, Journal of Neurology, Neurosurgery & Psychiatry.

[7]  E. Tolosa,et al.  Premotor signs and symptoms of multiple system atrophy , 2012, The Lancet Neurology.

[8]  Yen-ho Wang,et al.  Pulsed Wave Doppler Ultrasound Is Useful to Assess Vasomotor Response in Patients with Multiple System Atrophy and Well Correlated with Tilt Table Study , 2012, TheScientificWorldJournal.

[9]  Orthostatic Hypotension Is Differentially Associated with the Cerebellar Versus the Parkinsonian Variant of Multiple System Atrophy: a Comparative Study , 2012, The Cerebellum.

[10]  Jens Jordan,et al.  Consensus statement on the definition of orthostatic hypotension, neurally mediated syncope and the postural tachycardia syndrome , 2011, Clinical Autonomic Research.

[11]  L. Krakoff,et al.  Morbidity and mortality of orthostatic hypotension: implications for management of cardiovascular disease. , 2011, American journal of hypertension.

[12]  W. Meissner,et al.  Multiple system atrophy: current and future approaches to management , 2010, Therapeutic advances in neurological disorders.

[13]  O. Melander,et al.  Orthostatic hypotension predicts all-cause mortality and coronary events in middle-aged individuals (The Malmö Preventive Project) , 2009, European heart journal.

[14]  G. Wenning,et al.  Multiple system atrophy: an update , 2009, The Lancet Neurology.

[15]  G. Mancia,et al.  Hypovolaemia-induced metabolic dysfunction, mediated in part by aldosterone and angiotensin. , 2009 .

[16]  T. Thien,et al.  Orthostatic hypotension: revision of the definition is needed. , 2009, Journal of hypertension.

[17]  C. Mathias,et al.  Are current recommendations to diagnose orthostatic hypotension in Parkinson's disease satisfactory? , 2009, Movement disorders : official journal of the Movement Disorder Society.

[18]  W. Wieling,et al.  The consensus statement on the definition of orthostatic hypotension: a revisit after 13 years. , 2009, Journal of hypertension.

[19]  P Sandroni,et al.  Second consensus statement on the diagnosis of multiple system atrophy , 2008, Neurology.

[20]  P. Kempster,et al.  Clinical outcomes of progressive supranuclear palsy and multiple system atrophy. , 2008, Brain : a journal of neurology.

[21]  L-dihydroxyphenylserine ( Droxidopa ) : a new therapy for neurogenic orthostatic hypotension The US experience , 2008 .

[22]  H. Kaufmann L-dihydroxyphenylserine (Droxidopa): a new therapy for neurogenic orthostatic hypotension , 2008, Clinical Autonomic Research.

[23]  A. Dominiczak,et al.  2007 Guidelines for the Management of Arterial Hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC) , 2007, European heart journal.

[24]  Piotr Ponikowski,et al.  2007 Guidelines for the management of arterial hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). , 2007, European heart journal.

[25]  A. Sharrett,et al.  Orthostatic Hypotension Predicts Mortality in Middle-Aged Adults: The Atherosclerosis Risk in Communities (ARIC) Study , 2006, Circulation.

[26]  P. Low,et al.  What is the minimum duration of head-up tilt necessary to detect orthostatic hypotension? , 2005, Clinical Autonomic Research.

[27]  Sid Gilman,et al.  Development and validation of the Unified Multiple System Atrophy Rating Scale (UMSARS) , 2004, Movement disorders : official journal of the Movement Disorder Society.

[28]  E. Kerwin,et al.  Addition of montelukast or salmeterol to fluticasone for protection against asthma attacks: a randomized, double-blind, multicenter study. , 2004, Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology.

[29]  E. Benarroch Brainstem in Multiple System Atrophy: Clinicopathological Correlations , 2003, Cellular and Molecular Neurobiology.

[30]  D. Goldstein,et al.  Association Between Supine Hypertension and Orthostatic Hypotension in Autonomic Failure , 2003, Hypertension.

[31]  I. Biaggioni,et al.  Hypertension in orthostatic hypotension and autonomic dysfunction. , 2002, Cardiology clinics.

[32]  E. Benarroch New findings on the neuropathology of multiple system atrophy , 2002, Autonomic Neuroscience.

[33]  O. Rascol,et al.  Orthostatic Hypotension in Patients with Parkinson’s Disease , 2001, Drugs & aging.

[34]  P. Low,et al.  A double-blind, dose-response study of midodrine in neurogenic orthostatic hypotension , 1998, Neurology.

[35]  J. Jordan,et al.  The hypertension of autonomic failure and its treatment. , 1997, Hypertension.

[36]  R. Freeman,et al.  Efficacy of midodrine vs placebo in neurogenic orthostatic hypotension. A randomized, double-blind multicenter study. Midodrine Study Group. , 1997, JAMA.

[37]  J. Jankovic,et al.  Consensus statement on the definition of orthostatic hypotension, pure autonomic failure and multiple system atrophy , 2005, Clinical Autonomic Research.

[38]  R. Godwin-Austen,et al.  Autonomic Failure , 1989 .